Haemonetics (HAE)

• Market cap: $2.86B
• 1 day: -0.30%
• 5 days: -5.58%
• 1 month: -10.94%
• 3 months: -24.24%
• 6 months: -23.87%
• Year to date: -27.30%
• 1 year: -31.83%
• 5 years: -46.95%
• 10 years: 33.99%
• Sector: Healthcare
• Industry: Medical Devices

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,657

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

40% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 88

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

17% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 41

4.43% more ownership

Funds ownership: 108.19% [Q3] → 112.61% (+4.43%) [Q4]

2% more call options, than puts

Call options by funds: $42.5M | Put options by funds: $41.7M

1% more funds holding

Funds holding: 303 [Q3] → 305 (+2) [Q4]

1% less capital invested

Capital invested by funds: $4.45B [Q3] → $4.42B (-$31.7M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $95 67% upside
• Avg. target: $104 82% upside
• High target: $115 102% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson 22% 1-year accuracy 27 / 121 met price target	82% upside $104	Buy Maintained	18 Mar 2025
Raymond James Andrew Cooper 0% 1-year accuracy 0 / 16 met price target	102% upside $115	Strong Buy Reiterated	7 Feb 2025
JMP Securities David Turkaly 26% 1-year accuracy 7 / 27 met price target	75% upside $100	Market Outperform Maintained	7 Feb 2025
Barrington Research Michael Petusky 17% 1-year accuracy 12 / 70 met price target	67% upside $95	Outperform Maintained	7 Feb 2025